188 related articles for article (PubMed ID: 37313656)
1. PD1
Wu C; Duan L; Li H; Liu X; Cai T; Yang Y; Yin Y; Chang W; Zhong L; Zhang L; Cheng Y; Qin H; Wen Z; Wang H; Mai S
Clin Transl Med; 2023 Jun; 13(6):e1303. PubMed ID: 37313656
[TBL] [Abstract][Full Text] [Related]
2. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
3. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
Qiu Y; Ye W; Wang C; Zang J
Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
[TBL] [Abstract][Full Text] [Related]
5. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
8. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
9. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response.
Zhang L; Li Y; Zhou L; Zhou H; Ye L; Ou T; Hong H; Zheng S; Zhou Z; Wu K; Yan Z; Thiery JP; Cui J; Wu S
Cancer Res; 2023 Jun; 83(11):1834-1850. PubMed ID: 36939388
[TBL] [Abstract][Full Text] [Related]
10. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
11. Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
Wang J; Li X; Chen S; Cao J; Fan X; Wang H; Zhang X; Yang L
Life Sci; 2023 Dec; 335():122253. PubMed ID: 37951536
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
13. G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer.
Duan L; Liu X; Luo Z; Zhang C; Wu C; Mu W; Zuo Z; Pei X; Shao T
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456499
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8
Yu A; Hu J; Fu L; Huang G; Deng D; Zhang M; Wang Y; Shu G; Jing L; Li H; Chen X; Yang T; Wei J; Chen Z; Zu X; Luo J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802603
[TBL] [Abstract][Full Text] [Related]
16. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
18. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
[TBL] [Abstract][Full Text] [Related]
19. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
20. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
Lin H; Fu L; Zhou X; Yu A; Chen Y; Liao W; Shu G; Zhang L; Tan L; Liang H; Wang Z; Deng Q; Wang J; Jin M; Chen Z; Wei J; Cao J; Chen W; Li X; Li P; Lu J; Luo J
Cancer Lett; 2024 Jul; 593():216807. PubMed ID: 38462037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
